COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02864030
Recruitment Status : Active, not recruiting
First Posted : August 11, 2016
Last Update Posted : August 23, 2018
Mario Negri Institute for Pharmacological Research
Information provided by (Responsible Party):
Oncologia Medica dell'Ospedale Fatebenefratelli

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018